ALPMF (Astellas Pharma) Loans Receivable : $0 Mil (As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Loans Receivable?

Astellas Pharma's Loans Receivable for the quarter that ended in Sep. 2024 was $0 Mil.

Astellas Pharma Loans Receivable Historical Data

The historical data trend for Astellas Pharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Loans Receivable Chart

Astellas Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Loans Receivable

Get a 7-Day Free Trial

Astellas Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Astellas Pharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Astellas Pharma Loans Receivable Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.